Patents by Inventor Steven Howard
Steven Howard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12754260Abstract: Current sensing techniques. In an example, a current sensing method includes: generating a first magnetic field measurement; generating a second magnetic field measurement; generating a frequency estimate of a current; calculating a root-mean-square (RMS) value of an estimated amplitude of the current; and generating a temperature estimate of an integrated circuit (IC) configured to perform the method. The method also includes generating a first weighting factor and a second weighting factor based on the frequency estimate, the RMS value, and the temperature estimate, the first weighting factor to control amplification of the first magnetic field measurement and the second weighting factor to control amplification of the second magnetic field measurement.Type: GrantFiled: July 28, 2022Date of Patent: October 6, 2026Assignee: TEXAS INSTRUMENTS INCORPORATEDInventors: Lei Ding, Srinath Mathur Ramaswamy, Dok Won Lee, Steven Howard
-
Publication number: 20260176265Abstract: Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein R1, R2, R3 and Q1 are each as defined in the specification. The compounds are inhibitors of EGFR, including mutated forms of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (e.g. A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation) that confer resistance to existing EGFR inhibitors.Type: ApplicationFiled: October 19, 2023Publication date: June 25, 2026Inventors: Michael J. Waring, Hannah L. Stewart, Matthew P. Martin, Manon Sturbaut, Steven Howard, David Geoffrey Twigg, John Walter Liebeschuetz
-
Publication number: 20260176289Abstract: Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: November 10, 2023Publication date: June 25, 2026Inventors: Symon Gathiaka, Shuhei Kawamura, Matthew J. Mitcheltree, Anandan Palani, Juan del Pozo, Uma Swaminathan, Hua Zhou, Yu Kobayakawa, Satoru Iguchi, Hitomi Kondo, Keiichi Sumiyama, Patrick Schöpf, Steven Howard, George Madalin Giambasu, Melanie A. S. Blackburn, Solomon Kattar, Igri Kolaj, Bing Li, Michael Ryan, Emily Ruan, Tobias Sandmeier, David L. Sloman, Tomohiro Yamamoto, Makoto Kitade, Junpei Koyama, Tsuyoshi Oshima, Kei Akemoto, Toshihiro Sakamoto, Hiroki Asakura, Risako Miura
-
Patent number: 12655137Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: GrantFiled: October 19, 2023Date of Patent: June 16, 2026Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts
-
Publication number: 20260146042Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.Type: ApplicationFiled: July 30, 2025Publication date: May 28, 2026Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
-
Publication number: 20260137703Abstract: Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein R1, V1, RN and Q1 are each as defined in the specification. The compounds are inhibitors of EGFR, including mutated forms of EGFR (for example EGFR comprising a T790M mutation, a deletion in exon 19 (e.g. A740-A750), an exon 20 insertion, a mutation at L858R and/or a C797S mutation) that confer resistance to existing EGFR inhibitors.Type: ApplicationFiled: October 19, 2023Publication date: May 21, 2026Inventors: Michael J. Waring, Hannah L. Stewart, Matthew P. Martin, Islam H. Al-Khawaldeh, Jack T. Herbert, Steven Howard, David Geoffrey Twigg, John Walter Liebeschuetz, Jeffrey David St. Denis
-
Publication number: 20260102394Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: September 17, 2025Publication date: April 16, 2026Applicants: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.Inventors: Steven HOWARD, John Walter LIEBESCHUETZ, Tadashi SHIMAMURA
-
Publication number: 20250375110Abstract: A catheter device may include a body. The body can include a handle body, an actuator, a force sensor, and a displacement sensor. The catheter device may include a scaffold. The scaffold can include a plurality of splines. Each of the plurality of splines can extend transversely and longitudinally along the body. The deployable scaffold can move between a first position to a second position and all positions in-between. The catheter device may further include a shaft assembly. The shaft assembly can include an outer shaft and inner shaft coupled to the body portion. In the first position, the scaffold can be in a collapsed state. In the second position, the scaffold can be in an expanded state. The force sensor and displacement sensor may be located in the body to measure force and/or displacement translated by the inner and outer shaft from the scaffold.Type: ApplicationFiled: June 5, 2025Publication date: December 11, 2025Inventors: Chris Hasselwander, Steven Howard, Bradley Klos
-
Patent number: 12458640Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: GrantFiled: August 20, 2020Date of Patent: November 4, 2025Assignees: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.Inventors: Steven Howard, John Walter Liebeschuetz, Tadashi Shimamura
-
Patent number: 12440200Abstract: A soft tissue retraction system may include a support body. A soft tissue retraction system may include a bone engaging concavity on a first side of the support body. A soft tissue retraction system may include a soft tissue retracting surface on a second side of the support body. The system may include a first guide configured to receive a first pin to anchor the first pin into a bone when the bone is positioned within the bone engaging concavity. The system may include a second guide configured to receive a second pin to anchor the second pin into the bone when the bone is positioned within the bone engaging concavity.Type: GrantFiled: January 12, 2024Date of Patent: October 14, 2025Assignee: RetractOrtho, Inc.Inventors: Alidad Ghiassi, Steven Howard, Bradley Klos, Michael Bauschard
-
Publication number: 20250296930Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: December 9, 2024Publication date: September 25, 2025Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
-
Publication number: 20250092027Abstract: The invention provides a compound of formula (1). or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.Type: ApplicationFiled: July 9, 2024Publication date: March 20, 2025Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
-
Publication number: 20250074900Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.Type: ApplicationFiled: July 26, 2024Publication date: March 6, 2025Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Steven HOWARD, Benjamin David CONS, Jeffrey David ST. DENIS, Charlotte Mary GRIFFITHS-JONES, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Alan Richard BURNS, David COUSIN, Hannah Louise DEXTER, Guillaume François PARRA, John Paul WATTS, Robert JEWELL, Jennifer Ann STOCKWELL, Kim Louise HIRST, Isabelle Anne LEMASSON, David John NASH, James Daniel OSBORNE, Jonas Calleja PRIEDE, Nicholas Paul RICHARDS, Aaron Michael DUMAS, Brian Christopher BISHOP, David PARRY-JONES, Jeremy Peter SCOTT, Meenakshi Sundaram SHANMUGHAM, Peter Richard MULLENS, David Charles LATHBURY, Darren James DIXON, Matthew James GAUNT
-
Patent number: 12202828Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.Type: GrantFiled: December 21, 2022Date of Patent: January 21, 2025Assignee: ASTEX THERAPEUTICS LIMITEDInventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
-
Publication number: 20240368136Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.Type: ApplicationFiled: October 19, 2023Publication date: November 7, 2024Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Valerio BERDINI, Ildiko Maria BUCK, James Edward Harvey DAY, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Steven HOWARD, Christopher William MURRAY, David NORTON, Marc O'REILLY, Alison Jo-Anne WOOLFORD, Michael Liam COOKE, David COUSIN, Stuart Thomas ONIONS, Jonathan Martin SHANNON, John Paul WATTS
-
Publication number: 20240350233Abstract: An orthodontic device can include a bracket configured to support an orthodontic wire. The orthodontic device can include a locking assembly coupled to the bracket and switchable between a plurality of operational modes. The plurality of operational modes can comprise a first sliding mode in which the orthodontic wire is slidable relative to the bracket and a second locked mode in which the orthodontic wire is slidably locked relative to the bracket.Type: ApplicationFiled: July 2, 2024Publication date: October 24, 2024Inventors: Kami Hoss, Steven Howard, Jacob A. Moebius
-
Patent number: 12089871Abstract: A depth sensing dilator system for dilating a penetration in a tissue plane includes an elongate flexible body, having a proximal end and a distal end. The body has a tapered dilator segment, and at least a first electrode on a distal end of the body. The system includes a processor and a user interface output device. The processor is configured to send a first signal to the output device when a change in impedance at the first electrode indicates that the first electrode has reached a predetermined relationship with the tissue plane.Type: GrantFiled: August 25, 2021Date of Patent: September 17, 2024Assignee: Cross Vascular, Inc.Inventors: Steven Howard, Marshall L. Sherman, Randell Werneth, Bradley Klos
-
Patent number: 12077526Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.Type: GrantFiled: January 25, 2023Date of Patent: September 3, 2024Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Steven Howard, Benjamin David Cons, Jeffrey David St. Denis, Rhian Sara Holvey, Guillaume François Parra, Kim Louise Hirst, Isabelle Anne Lemasson, David John Nash, James Daniel Osborne, Jonas Calleja Priede, Nicholas Paul Richards, Aaron Michael Dumas, Brian Christopher Bishop, David Parry-Jones, Meenakshi Sundaram Shanmugham, Darren James Dixon, Matthew James Gaunt
-
Patent number: 12071429Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.Type: GrantFiled: February 1, 2021Date of Patent: August 27, 2024Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
-
Patent number: D1112172Type: GrantFiled: November 17, 2023Date of Patent: February 10, 2026Assignee: Freedman Electronics Pty LtdInventors: Pieter Schillebeeckx, Samuel Trewartha, Steven Howard